Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

Nat Commun. 2022 Oct 23;13(1):6309. doi: 10.1038/s41467-022-33985-4.


Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / chemistry
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Ferritins
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles*
  • SARS-CoV-2 / genetics
  • Severe acute respiratory syndrome-related coronavirus*
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines*


  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Viral Vaccines
  • Ferritins
  • spike protein, SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants